Corneal biometry changes with 0.01% atropine for myopia control: a randomised controlled trial and case of incidental keratoconus - Nature

AcknowledgementsThe authors would like to acknowledge Marianne van Veen for her effort in enrolling patients for the CORRBI biobank; Jacoline ten Brink for her effort in collecting and preparing Amsterdam Glaucoma Study samples; and Uxía Regueiro and Daniël S. Stieber for their effort in preparing and delivering the samples and data from Utrecht Medical University Center. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, and RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data, and Jard de Vries, MSc, and Linda Broer, PhD, for their valuable analytical insights and input throughout the project.

ORCID: orcid.org/0000-0003-4813-28061,3,4 We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply. AbstractThis study was conducted to determine the effect of Endometriosis Nursing Care Program (ENCP), developed in line with Health Promotion Model for women with endometriosis, on women's quality of life and healthy lifestyle behaviours. This prospective, single-centre, randomized controlled trial was conducted with 46 women diagnosed with endometriosis who applied to the Endometriosis Outpatient Clinic of a training research hospital. Women with an Endometriosis Health Profile Questionnaire-5 (EHP-5) score ≥ 22 indicating reduced quality of life were included. Participants were randomly assigned to an intervention group (n = 23) receiving Endometriosis Nursing Care Program (ENCP) or a control group (n = 23) receiving routine care. The ENCP consisted of two individual 60-min sessions delivered two weeks apart. The primary outcome was change in quality of life measured by EHP-5.

A large-scale study, presented today at UEG Week 2026, has identified distinct antibody patterns up to 10 years before the diagnosis of inflammatory bowel disease (IBD), potentially opening new avenues for earlier risk detection and providing insights into future disease course. IBD is a group of chronic conditions, including Crohn's disease (CD) and ulcerative colitis (UC), in which abnormal immune responses contribute to ongoing inflammation and damage in the digestive system. Although IBD is increasingly recognized to develop over a prolonged period before diagnosis, relatively little is known about the immune changes that occur during this time.

Antibiotic use from childhood through early adulthood was associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today at UEG Week 2026. IBS is a common digestive disorder that affects more than 60 million people across Europe, causing symptoms such as abdominal pain and changes in bowel habits. Whilst previous research has suggested a link between antibiotic use and IBS, evidence on whether childhood exposure is associated with IBS in adulthood remains inconsistent. Much of the existing evidence relies on people recalling past antibiotic use, with a lack of population-based studies using objectively recorded antibiotic data across childhood.

AN EXPERIMENTAL vaccine designed to prevent invasive Escherichia coli infections in older adults has failed to demonstrate clinical efficacy in a large Phase III trial, despite generating robust and sustained immune responses. The E.mbrace trial, involving 17,701 participants across 20 countries, found no demonstrated protective benefit from the nine-valent ExPEC9V vaccine compared with placebo. Following a prespecified futility analysis, the study was terminated early, and development of the vaccine has been discontinued.